

RESEARCH ARTICLE

Gene Expression Deconvolution for Uncovering Molecular Signatures in Response to Therapy in Juvenile Idiopathic Arthritis

Ang Cui^{1☯[‡]✉}, Gerald Quon^{2☯[‡]✉}, Alan M. Rosenberg³, Rae S. M. Yeung^{4,5*}, Quaid Morris^{2,6,7*}, BBOP Study Consortium[†]

1 Division of Engineering Science, University of Toronto, Toronto, ON, Canada, **2** Department of Computer Science, University of Toronto, Toronto, ON, Canada, **3** Department of Pediatrics, Division of Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, **4** Divisions of Rheumatology and Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada, **5** Departments of Paediatrics, Immunology and Medical Sciences, University of Toronto, Toronto, ON, Canada, **6** The Donnelly Centre, University of Toronto, Toronto, ON, Canada, **7** Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

☯ These authors contributed equally to this work.

✉ Current address: Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, United States of America

✉ Current address: Molecular and Cellular Biology, University of California Davis, Davis, CA, United States of America

† Complete membership of the author group can be found in the Acknowledgments.

* rae.yeung@sickkids.ca (RY); quaid.morris@utoronto.ca (QM)



OPEN ACCESS

Citation: Cui A, Quon G, Rosenberg AM, Yeung RSM, Morris Q, BBOP Study Consortium (2016) Gene Expression Deconvolution for Uncovering Molecular Signatures in Response to Therapy in Juvenile Idiopathic Arthritis. PLoS ONE 11(5): e0156055. doi:10.1371/journal.pone.0156055

Editor: Paul Proost, University of Leuven, Rega Institute, BELGIUM

Received: August 19, 2015

Accepted: May 9, 2016

Published: May 31, 2016

Copyright: © 2016 Cui et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data will be made available to interested researchers upon approval by the BBOP Study Steering Committee as required by the patient consent acquired for this study. Requests for data access can be submitted to Dr. Alan M. Rosenberg (alan.rosenberg@usask.ca) and Dr. Rae S.M. Yeung (rae.yeung@sickkids.ca), who will forward the request to the BBOP Study Steering Committee.

Funding: This study was funded by a Natural Sciences and Engineering Research Council (NSERC) operating grant and an Early Researcher

Abstract

Gene expression-based signatures help identify pathways relevant to diseases and treatments, but are challenging to construct when there is a diversity of disease mechanisms and treatments in patients with complex diseases. To overcome this challenge, we present a new application of an *in silico* gene expression deconvolution method, ISOpure-S1, and apply it to identify a common gene expression signature corresponding to response to treatment in 33 juvenile idiopathic arthritis (JIA) patients. Using pre- and post-treatment gene expression profiles only, we found a gene expression signature that significantly correlated with a reduction in the number of joints with active arthritis, a measure of clinical outcome (Spearman rho = 0.44, p = 0.040, Bonferroni correction). This signature may be associated with a decrease in T-cells, monocytes, neutrophils and platelets. The products of most differentially expressed genes include known biomarkers for JIA such as major histocompatibility complexes and interleukins, as well as novel biomarkers including α-defensins. This method is readily applicable to expression datasets of other complex diseases to uncover shared mechanistic patterns in heterogeneous samples.

Introduction

Juvenile idiopathic arthritis (JIA) is a family of heterogeneous autoimmune diseases characterized by chronic joint inflammation in children [1]. In JIA, prolonged joint inflammation leads to joint damage and subsequent functional disability [2–6]. However, the etiology of JIA remains unknown, and clinical parameters alone are inadequate to predict patient response to

Award from the Ontario Research Fund to QM, team grants from the Canadian Institutes of Health Research (CIHR grant numbers 82517 and QNT-69301), Canadian Arthritis Network (SRI-IJD-01), and The Arthritis Society. Additional funding was provided by the University of Saskatchewan, Manitoba Institute of Child Health, McGill University, Memorial University, University of British Columbia, and University of Sherbrooke.

Competing Interests: The authors have declared that no competing interests exist.

Abbreviations: ACR, American College of Rheumatology; BBOP, Biologically-Based Outcome Predictors in JIA Consortium; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; ILAR, International League of Associations for Rheumatology; JIA, juvenile idiopathic arthritis; LRM, limited range of motion; MHC, major histocompatibility complex; NSAID, non-steroidal anti-inflammatory drugs; PBMC, peripheral blood mononuclear cell; PGA, physician's global assessment; RF, rheumatoid factor; Th, T helper subset (e.g. Th1, Th17).

treatment. Consequently, there is a need to study the pathways affected by these diseases at the molecular level.

Molecular profiling has contributed to improved understanding of risk for progression and responses to treatment in JIA [7]. Transcriptional profiling for studies of immune diseases is often carried out on whole blood or peripheral blood mononuclear cells (PBMCs) as they likely include immune cells that reflect disease status, and are readily obtained by routine phlebotomy. Gene expression profiling has demonstrated the important role of specific cell types in JIA pathogenesis and identified potential mechanisms for clinical remission [8]. Expression profiling and genotyping have been used together to identify genetic or transcriptional variations associated with patient response to treatment [9]. In this study, gene expression profiles and clinical indicators of disease activity are measured pre- and post-treatment for multiple patients. Genes whose differences between pre- and post-treatment highly correlate with clinical response are candidate biomarkers of disease activity or targets for therapeutic intervention.

A major obstacle in identifying biomarkers for JIA treatment response arises from the difficulty in uncovering commonality across a population with diverse clinical profiles and patient-specific expression patterns. JIA encompasses diseases with a wide spectrum of clinical symptoms, progression and outcomes [10]. The International League of Associations for Rheumatology (ILAR) identified seven classes of JIA based on clinical symptoms at disease onset. Within each class, patients exhibit a wide variation with respect to disease course and treatment response. Furthermore, the specific treatment options and permutations of combined treatments are diverse, resulting in distinct expression signatures in each individual. This drives the need to develop a computational approach that combines expression profiles from a group of individuals with similar conditions to uncover the commonality in the course of treatment.

To identify common molecular signatures in a group of subjects, Quon et al. developed ISOpure-S1, a computational gene expression deconvolution method, to characterize a single, common cancer expression profile from heterogeneous tumor profiles [11, 12]. The method utilizes probabilistic algorithms to separate raw expression profiles into individual components, corresponding to the common cancer gene expression patterns across patients and healthy cells mixed into the tumor tissues. They found that ISOpure-S1's estimation of cancer content in patient's tissue was well correlated with pathologists' estimates. Previous work has also demonstrated the robustness of similar deconvolution methods for inferring cellular composition of blood samples and identifying expression signatures in diseases [13–15].

In this pilot study, we present a new application of ISOpure-S1 to identify the common gene expression signature in response to treatment in JIA. We applied this method to whole blood samples drawn from 33 JIA patients pre-treatment and 6 months post-treatment to uncover the net effect of disease-modifying drugs. The model identified a common “treatment response” signature in all 33 patients despite their clinical heterogeneity. It then estimated a per-patient scalar parameter “% treatment response” that reflected the overall magnitude of the “treatment-response” signature observed in each post-treatment expression profile. We found the estimate for % treatment response significantly correlated with a clinical measure of treatment response. We also identified a list of differentially expressed genes that may aid in the understanding of JIA disease progression and treatment responses.

Materials and Methods

Ethics statement

This study is a part of the larger “Biologically-Based Outcome Predictors in JIA” (BBOP study) multi-center cohort study carried out in 11 Canadian academic health sciences centers. All of

the institutional ethics review boards (listed in Acknowledgments) from each of the participating sites specifically approved this study. All participants provided their written consent to participate in this study using a paper-based consent form and process approved by each of the respective ethics review boards from each of the participating institutions. Informed written consent for a minor child was obtained from the child’s parent or legal guardian on behalf of the minor children enrolled in this study using consent forms and processes approved by the respective ethics review boards of each of the participating institutions. Informed written assent was obtained from minor children who were considered capable of providing assent. The assent form and processes for obtaining assent were approved by the respective ethics review boards of each of the participating institutions.

Clinical samples

Children less than 16 years of age with new onset JIA were eligible for inclusion in this study. Detailed clinical and biological data were collected using uniform data collection instruments and standard operating procedures, including detailed clinical and gene expression data on each individual at baseline (time of diagnosis/study enrollment) and at 6 months after treatment. A proof of principle study on 33 paired patient samples at baseline and 6 months was performed. These 33 patients were diagnosed with different JIA subtypes as classified by ILAR criteria [1]. The study group comprised 18 polyarticular rheumatoid factor negative (RF-), seven polyarticular rheumatoid factor positive (RF+), five systemic, one oligoarticular, one psoriatic and one undifferentiated patients. The patients were recruited from the following sites: nine from BC Children’s Hospital, Vancouver, six from Montreal Children’s Hospital, six from Manitoba Health Sciences Center, four from The Hospital for Sick Children, Toronto, three from Janeway Hospital, St John’s, three from IWK Hospital, Halifax, one from the University of Saskatchewan, Saskatoon, and one from Stollery Children’s Hospital, Edmonton. There were 26 female patients in the dataset (79%). Table 1 summarizes the clinical characteristics of the patient cohort. Four patients had been treated with disease-modifying anti-rheumatic drugs (DMARDs) prior to the pre-treatment blood draw and therefore their pre-treatment profiles were excluded from the study. 15 of the 29 DMARD-naïve patients received non-steroidal anti-inflammatory drugs (NSAIDs) prior to the pre-treatment blood draw. Between the baseline and 6-month blood draws, patients, in addition to receiving an NSAID, were prescribed one or more of the following drugs: Cyclosporin, Hydroxychloroquine, Methotrexate, Sulfasalazine (DMARDs); Anakinra, Etanercept (Biologic therapies); and/or Prednisone.

Microarray data collection

Blood samples were collected, transported and processed in accordance with strict standard operating procedures. Briefly, peripheral blood was collected in Tempus Blood RNA Tubes

Table 1. Measures of disease activity in patient cohort.

	0 months	6 months
Physician’s global assessment (PGA), median (IQR)	4.9 (2.1–6.4)	1.2 (0.1–2.2)
Erythrocyte sedimentation rate (ESR), median (IQR)	20 (8–54)	9 (3–16)
Number of active joints, median (IQR)	10 (6–18)	2 (0–10)
Number of LRM (limited range of motion) joints, median (IQR)	5 (3–14)	1 (0–3)

Internationally accepted measures of disease activity including those in the ACR pediatric core set at baseline and 6 months.

doi:10.1371/journal.pone.0156055.t001

(Applied Biosystems), which contain a proprietary reagent to lyse blood cells upon collection and permit stable storage and transportation of total RNA and transported to a central processing site within 5 days [16]. RNA was purified at a central biorepository using proprietary buffer according to the manufacturer’s instructions using the Tempus Spin RNA Isolation Reagent Kit (Applied Biosystems). RNA samples were assayed for quality (A260:A280 and A260:A230 ratios >1.8; RIN >7.0; Agilent BioAnalyzer) and concentration prior to labeling and processing. Whole genome gene expression profiles were determined using Illumina Human HT-12 Expression BeadChip Arrays. Each array targets more than 47,000 probes designed to cover genes from NCBI RefSeq Release 38 as well as legacy UniGene genes.

Computational approach

ISOpure was previously developed to improve the analysis accuracy of tumor expression profiles [12]. It consists of two steps; here only the first step (ISOpure-S1) was used to capture a common change in expression profiles across all JIA patients, with which the biomarkers associated with response to treatment were identified.

A geometric intuition for our model is shown in Fig 1. ISOpure-S1 deconvolves, or separates, each post-treatment expression profile into a treatment-naïve component and a treatment-response component, where the treatment-naïve component is estimated from a linear combination of all patients’ pre-treatment profiles. For each post-treatment expression profile, ISOpure-S1 identifies a “residual” gene expression pattern that cannot be explained by any combination of the pre-treatment profiles. This residual profile thus comprises patterns due to treatment response as well as measurement noise. ISOpure-S1 estimates a single common treatment-response profile that best explains all of the residuals observed for each of the post-treatment profiles. The gene expression patterns that cannot be attributed to pre-treatment profiles or the treatment-response profile are considered individual variations in response to treatment and/or noise and not modeled. The model also computes a “% treatment response” scalar per patient, which represents the predicted size of the treatment response in the post-treatment profile. Because ISOpure-S1 deconvolves post-treatment profiles using the pre-treatment profiles of all patients for which these data are available, this treatment-response profile




Fig 1. Graphical representation of the ISOpure-S1 algorithm. The ISOpure-S1 algorithm is based on a probabilistic topic model. We modeled post-treatment gene expression profiles as mixtures of hidden profiles corresponding to treatment-response and treatment-naïve portions, and removed the gene expression signals of the treatment-naïve portion using pre-treatment expression profiles. (A) We modeled the post-treatment expression profile as a weighted average of the gene expression profiles of treatment-response and treatment-naïve profiles. (B) We inferred a single common treatment-response profile after drug treatment across all patients that corresponds to the portion of the post-treatment profiles that cannot be attributed to any pre-treatment profiles. (C) We used this inferred treatment-response profile to estimate the % treatment-response content in each patient. Steps (B) and (C) were done iteratively during the maximum likelihood estimation procedure.

doi:10.1371/journal.pone.0156055.g001

automatically excludes patient-specific signatures. Finally, the genes targeted by the treatment can be predicted by a delta profile, which is obtained by comparing the treatment-response profile to the pre-treatment profiles.

ISOpure-S1 takes as input $M (= 29)$ pre-treatment and $N (= 33)$ post-treatment gene expression profiles (ISOpure-S1 does not require the numbers of pre- and post-treatment profiles to be equal). Four pre-treatment profiles were removed because the patients were taking DMARDs prior to their first blood draws. The model outputs four parameters of interest: 1) a single treatment-response gene expression profile common to all patients, 2) a % treatment-response estimate for each post-treatment expression profile, 3) a single delta profile that captures the difference between the treatment-response profile and the pre-treatment profiles, and 4) a list of genes predicted to be differentially expressed under treatment in the delta profile. The MATLAB commands for running ISOpure-S1 are included as [S1 File](#).

Model description

In the following model description, variables are in italics, constants are in upper case, vectors are in bold, and index references are in italic lowercased letters. The notation $[u \ v]$ represents a matrix constructed by horizontally appending column vectors and/or matrices u and v . The notation Mv represents matrix-vector product of M and v . The notation \hat{p} represents the estimation of variable p .

The input to ISOpure-S1 is a set of expression profiles b_m from M pre-treatment blood samples, and p_n from N post-treatment blood samples.

Let the matrices B and P be defined as

$$B = [b_1 \dots b_M]$$

$$P = [p_1 \dots p_N]$$

where each pre-treatment profile b_m and post-treatment profile p_n is composed of non-negative expression measurements from G genes. ISOpure-S1 estimates a single, non-negative treatment-response profile denoted as r . b_m, p_n and r are column vectors with G elements. Our model requires the vector p_n to be a “count” vector that contains non-negative integers; if this vector is initially real-valued, it can be re-scaled and discretized to achieve the desired precision in representation of the gene expression levels. Each pre-treatment profile b_m is scaled such that all its G entries sum to 1 and, as such, it can be interpreted as discrete probability distribution over transcripts. The treatment-response profile, r , inferred by the model also sums to 1 and permits a similar interpretation.

ISOpure-S1 models each post-treatment profile as a non-negative, convex combination (mixture) of pre-treatment profiles in B and the treatment-response profile r , and uses $\theta_{n,d}$, where $d \in \{1, \dots, M+1\}$, to indicate the convex weight of these profiles. The θ_n vector is restricted such that the $(M+1)$ entries in each θ_n sum to 1, so that θ_n corresponds to a discrete probability distribution over profiles.

$$\hat{p}_n = [B \ r] \theta_n$$

$$P(p_n | B, r, \theta_n) \sim \text{Multinomial}(p_n | \hat{p}_n)$$

The hidden variables θ_n are initialized such that all entries are equal to $1/(M+1)$. θ_n are inferred using *Maximum A Posteriori* (MAP) estimation from a Dirichlet prior v , which is initialized to be a set of random numbers greater than 1 for the first 1 to M entries, and greater than 5 for the $(M+1)$ th entry. The $(M+1)$ th entry is the proportion of the expression profile

associated with the treatment-response profile. We assign a larger prior for this proportion because there are M profiles capturing the treatment-naive portion and only one profile capturing the treatment-response portion.

$$P(\theta_n | \mathbf{v}) \sim \text{Dirichlet}(\theta_n | \mathbf{v})$$

The treatment-response profile, \mathbf{r} , is also inferred using MAP from a Dirichlet prior, which is constructed by a convex combination of pre-treatment profiles \mathbf{B} . The convex weights are denoted by $\boldsymbol{\omega}$ and the strength between the treatment-response profile and its prior is denoted as κ , which is initialized to 10,000.

$$P(\mathbf{r} | \kappa, \boldsymbol{\omega}, \mathbf{B}) \sim \text{Dirichlet}(\mathbf{r} | \kappa \boldsymbol{\omega} \mathbf{B})$$

The complete log likelihood is defined as:

$$\begin{aligned} \ln L &= \ln P(\mathbf{p}, \boldsymbol{\theta}, \mathbf{r} | \mathbf{v}, \kappa, \boldsymbol{\omega}, \mathbf{B}) \\ &= \ln P(\mathbf{r} | \kappa, \boldsymbol{\omega}, \mathbf{B}) + \sum_{n=1}^N [\ln P(\theta_n | \mathbf{v}) + \ln P(\mathbf{p}_n | \mathbf{B}, \mathbf{r}, \theta_n)] \end{aligned}$$

θ_n , \mathbf{r} , \mathbf{v} , $\boldsymbol{\omega}$ and κ are estimated by maximizing the complete log likelihood function. 20 iterations of the optimization procedure were performed and yielded a relative change in log likelihood of less than 10^{-7} between the final two iterations. Each iteration procedure used the Polak-Ribière conjugate gradient descent method to estimate variables of the same type simultaneously (where we assigned the same letter to variables of the same type). To find a good local (and possibly global) maximum, 10 random initializations were performed and the one that achieves the highest complete likelihood was used.

To identify the differentially expressed genes, a delta profile, $\boldsymbol{\delta}$, was computed by comparing the treatment-response profile and a convex combination of pre-treatment profiles.

$$\boldsymbol{\delta} = \log_2(\mathbf{r}) - \log_2(\boldsymbol{\omega} \mathbf{B})$$

The genes with the highest fold changes (log2 differences) in the delta profile were identified as the differentially expressed genes after treatment.

Sensitivity test

The model sensitivity analysis was performed by dividing the total set of profiled genes into four subsets and applying ISOpure-S1 on each subset separately. The robustness was measured based on the standard error of the model parameters estimated on the subsets of the data.

Cell type analysis

To uncover the cell types associated with treatment response, a Spearman correlation test was performed between each delta profile and cell type profile published by Novershtern et al [17]. The probes were first centered by their mean across all samples before measuring Spearman correlation.

Results

Impact of treatment on gene expression is correlated with disease activity

We applied ISOpure-S1 to the 33 post-treatment profiles using the 29 pre-treatment profiles as a reference panel. Using *Maximum A Posteriori* (MAP) estimation, ISOpure-S1 simultaneously fits 1) an inferred treatment-response profile, and 2) 30 non-negative weights for each of the post-treatment profiles. These weights describe a convex combination of the 29 pre-treatment profiles and the inferred treatment-response profile (in other words, the weights are all between 0 and 1 and they sum to one) (Fig 2). Each weight corresponds to the proportion of the post-treatment profile explained by each of the 30 components (29 profiles in the reference panel




Fig 2. ISOpure-S1-inferred compositions of post-treatment profiles in terms of pre-treatment profiles and “treatment-response” profile. Each post-treatment profile was attributed to a combination of the pre-treatment profiles (column 1–29) and the “treatment-response” profile (column 30). The shading represents the percentage contribution from each of the pre-treatment profiles and the “treatment-response” profile.

doi:10.1371/journal.pone.0156055.g002




Fig 3. The per-patient % treatment-response estimates made by ISOpure-S1, sorted by increasing order (green dots). A sensitivity analysis was performed to verify the robustness of our results (blue dots), which was done by dividing the total set of profiled genes into four subsets and applying ISOpure-S1 on each subset separately. The % treatment-response estimates for each subset of the profile (blue dots) are similar to the original results (green dots) (average standard error = 0.019; maximum standard error = 0.057).

doi:10.1371/journal.pone.0156055.g003

and the one inferred treatment-response profile; the ‘% treatment response’ scalar is the weight of the treatment-response profile). For 23 of the 29 patients, the model automatically assigned their pre-treatment profile the highest weight in the deconvolution of their post-treatment profiles, despite the fact that the algorithm did not use sample pairing information. This result suggests that the strong, patient-specific gene expression patterns in raw expression profiles are removed in the inferred treatment-response profile.

There is wide variation in the % treatment-response estimates for the 33 patients (Fig 3). To confirm that the estimates are robust and not driven by small variations in the dataset, we performed a sensitivity test. We divided the total set of profiled genes into four subsets, and applied ISOpure-S1 on each subset separately. The % treatment-response estimates for each subset of the profile (blue dots) are similar to the original results (green dots), suggesting that the model is indeed robust (average standard error = 0.019; maximum standard error = 0.057).

Next, we compared our % treatment-response estimates with clinical indicators of disease activity. We measured four individual components of the validated ACR (American College of Rheumatology) pediatric core set measure of disease activity for JIA, including physician’s global assessment (PGA), erythrocyte sedimentation rate (ESR), % reduction in number of joints with active arthritis (active joints), and % reduction in joints with limited range of motion (LRM joints) [18]. These four clinical indicators are uncorrelated with each other except for the % reduction in active joint count and the % reduction in LRM joint count (S1 Table). We found that the % treatment-response estimate significantly correlated with a % reduction in number of active joints (Spearman rho = 0.44, p = 0.040; Pearson rho = 0.46, p = 0.032, Bonferroni correction) (Table 2, Fig 4). Individuals with high % treatment response consistently showed a decrease in the number of active joints, whereas the change in % of active joints was much more variable for individuals with low % treatment response (Fig 4, right panel). We recognized that systemic JIA patients might have more distinct disease mechanisms compared with the rest of the cohort. Therefore, we repeated this analysis without the five systemic JIA patients. The trend remained the same for the non-systemic JIA cohort (Spearman rho = 0.49, p = 0.032; Pearson rho = 0.48, p = 0.036, Bonferroni correction) (S1 Fig).

Table 2. Correlation between ISOpure-S1-predicted % treatment-response and % decrease in clinical indicators of disease activity.

Clinical indicator of disease activity	Correlation with % treatment-response estimates (Spearman)	Bonferroni-corrected p-value	Correlation with % treatment-response estimates (Pearson)	Bonferroni-corrected p-value
PGA	-0.037	1.000	-0.124	1.000
ESR	0.292	0.396	0.158	1.000
# Active Joints	0.443	0.040 *	0.457	0.032 *
# LRM Joints	0.114	1.000	0.173	1.000

* p<0.05

doi:10.1371/journal.pone.0156055.t002

Genes influenced by treatment are enriched for immune functions

To identify the cell types affected by the treatment of JIA, we compared our delta profile against the profiles of 38 known blood cell types [17]. First, we confirmed the absence of batch effects by calculating the correlation between the raw differences in each pair of patient profiles and the reference blood cell type profiles (S2 Fig). These two types of profiles did not cluster by study, indicating that the patient profiles from this study are comparable with reference blood cell type profiles. We then correlated the 38 reference blood cell types with the delta profile, which represents the changes in gene expression patterns associated with response to treatment. In this analysis, we assumed that the gene expression profile of each cell type remained relatively constant. However, it is worth noting that the drug treatments most likely impacted both cell type composition, as well as expression patterns in individual cell types. The delta




Fig 4. Correlation between expression-based % treatment-response estimate inferred by ISOpure-S1 and % reduction in number of active joints found in clinical record. Left: Correlation between % treatment-response estimate and % reduction in number of active joints (Pearson rho = 0.44, p = 0.010; Spearman rho = 0.46, p = 0.008). Right: The patients were divided evenly into three groups based on their % treatment-response estimates. The median and interquartile range of % reduction in number of active joints are indicated by box plots.

doi:10.1371/journal.pone.0156055.g004




Fig 5. A decrease in the proportion of T-cells, neutrophils, monocytes and platelets in blood may be associated with a response to drug treatment. We correlated the delta profile with the profiles of 38 known blood cell types. The red color indicates a decrease in their concentrations and the blue color indicates an increase in their concentrations in blood in response to drug treatment. The color bar indicates the Spearman correlation coefficients.

doi:10.1371/journal.pone.0156055.g005

profile is negatively correlated with the profiles of neutrophils, monocytes, T-cells and megakaryocytes (progenitor of platelets) suggesting that the decrease of these cell types in the blood may be associated with response to treatment (Fig 5). To verify this result, we examined the change in the cell counts measured in phlebotomy. Indeed, there was a 4.05% median decrease in white blood cell count (11.33% decrease in neutrophils and 5.00% decrease in lymphocytes) and 2.25% decrease in platelet count. In particular, there was a strong positive correlation between changes in platelet count and in the number of active joints (Spearman rho = 0.52, p = 0.009).

We identified the differentially expressed genes associated with treatment response by extracting the top up- and down-regulated genes in the delta profile (Table 3 and Page 1 in S2 Table). We performed functional enrichment analysis (DAVID) [19, 20] on the top 100 up- and down-regulated genes (S2 File), and found that these genes are enriched for immune functions (GO terms include immune response, defense response, and inflammatory response). The down-regulated genes contain markers of immune activation and are involved in host defense to infectious organisms, while the up-regulated genes contain those related to leukocyte recruitment and soluble mediators of the innate immunity. Many down-regulated genes also show a large decrease in the average raw expression values (Page 1 in S2 Table).

We summarized the functions of some up- and down-regulated genes that ISOpure identifies (Tables 4 and 5). A number of interleukin (IL) and IL receptor genes, including IL8, IL8RB (CXCR2), IL6R, and IL2RB were significantly over-expressed (among the top 100 up-regulated genes). Among the most down-regulated genes in our study, we also found well-known biomarkers for autoimmune diseases: the major histocompatibility complex class II (MHC II), DR beta (HLA-DRB). We also found some newer targets with very strong signals: α -defensins and type 1 interferon-inducible proteins. The α -defensin genes DEFA1, 1B, 2, 3 and 4 were all among the top 21 down-regulated genes. The most up- and down-regulated genes in the

Table 3. Top 20 up- and down-regulated genes identified by ISOpure-S1.

Up-regulated genes		Down-regulated genes	
Gene symbol	Fold change	Gene symbol	Fold change
LOC731682	2.65	DEFA3	-6.08
PDZK1IP1	2.34	DEFA1B*	-6.06
FCER1A	2.26	LOC649923	-5.96
IL8	2.05	DEFA1	-5.90
IL8RB	1.78	DEFA2*	-5.76
D4S234E	1.72	MGC29506	-5.74
NFXL1	1.63	IGJ	-5.70
MFF	1.59	ZDHHC19	-5.58
PTPRC	1.51	IFI44L	-5.37
FOS	1.51	LOC652775	-5.22
HOPX	1.50	IGLL1	-5.20
PI3	1.50	IFI27	-5.14
JMJD1C	1.49	ISG15	-5.10
ITM2B	1.49	TNFRSF17	-5.03
FFAR2	1.45	LOC652493	-4.95
MGC72104	1.43	C19ORF59	-4.90
LOC643319	1.41	ELA2	-4.79
MYL4	1.40	TXNDC5	-4.73
FAM126B	1.37	LOC652694	-4.67
DUSP1	1.37	HES4	-4.65

A list of the differentially expressed genes in the delta profile (impacted by treatment) and their fold changes (log2 differences).

* Reclassified as DEFA1

doi:10.1371/journal.pone.0156055.t003

analysis of non-systemic JIA patients were similar: all the genes in Tables 4 and 5 were among the top 600 down- and up-regulated genes in the non-systemic JIA analysis.

In contrast, the top 100 most significantly differentially expressed genes obtained by t-test (Page 2 in S2 Table) on the original expression profiles are not enriched for immune functions according to DAVID. These genes do not overlap with the top 100 up- and down-regulated genes obtained by ISOpure-S1. The gene product of most differentially expressed genes from the t-test include opioid receptor, ADP-ribosylation factor, calcium/calmodulin-dependent protein kinase, zinc-finger protein, and tumor necrosis factor (TNF) receptor. It is worth

Table 4. Selected highly up-regulated genes identified by ISOpure-S1 and their families.

Up-regulated genes after treatment	Differential expression fold changes [Rank]	Protein families
PDZK1IP1	2.34 [2]	PDZK1 Interacting protein
IL8	2.05 [4]	Interleukin
IL8RB (CXCR2)	1.78 [5]	
IL2RB	1.12 [66]	
IL6R	1.09 [77]	
PTPRC	1.51 [9]	Protein Tyrosine Phosphatase

Rank of fold change (log2 difference) in sorted delta profile is indicated in bracket.

doi:10.1371/journal.pone.0156055.t004

Table 5. Selected highly down-regulated genes identified by ISOpure-S1 and their families.

Down-regulated genes after treatment	Differential expression fold changes [Rank]	Protein families
DEFA3	-6.08 [1]	α-defensin
DEFA1B*	-6.06 [2]	
DEFA1	-5.90 [4]	
DEFA2*	-5.76 [5]	
DEFA4	-4.60 [21]	Type 1 interferon inducible gene product
IFI44L	-5.37 [9]	
IFI27	-5.14 [12]	
ISG15	-5.10 [13]	
HLA-DRB1	-3.06 [91]	
HLA-DRB5	-2.16 [218]	Major histocompatibility complex, class II, DR beta
HLA-DRB3	-2.02 [265]	
IL4R	-3.30 [67]	
IL17RA	-2.07 [244]	Interleukin
IL1R2	-2.00 [280]	
IL18RAP	-1.89 [326]	

Rank of fold change (log2 difference) in sorted delta profile is indicated in bracket.

* Reclassified as DEFA1

doi:10.1371/journal.pone.0156055.t005

noting that TRAF6, a molecule involved in TNF receptor family signaling and known to be associated with multiple autoimmune diseases including rheumatoid arthritis [21], was one of the most differentially expressed genes, indicating that a decrease in TRAF6 expression level may be associated with treatment effects in JIA.

Discussion

We explored the utility of ISOpure-S1 for uncovering a treatment-response profile in blood samples of JIA patients with different symptoms and treatments. We did this by deconvolving heterogeneous blood expression profiles using only whole blood samples. We found that many patient-specific expression signatures were successfully removed after deconvolution. The resulting % treatment-response estimates significantly correlated with a reduction in the number of joints with active arthritis, a clinical indicator of treatment response, despite the small cohort size, heterogeneity in medication use, and the absence of clinical information as model input. The common defining feature of the group of diseases described as JIA is joint inflammation (i.e. arthritis); therefore in spite of the heterogeneity of other clinical features among the different types of JIA the correlation with the % decrease in the number of joints with active arthritis is expected. The differentially expressed genes in the associated delta profile were enriched for immune functions, and we found that α-defensins and type 1 interferon-inducible proteins were likely impacted by treatment in JIA. The enrichment of immune function genes among differentially expressed genes is consistent with the central role of immune activation in inflammatory arthritis and the known mechanism of action of anti-inflammatory medications used in these children.

Our results show that a global decrease in T-cell, neutrophil, monocyte and platelet concentrations may be associated with response to treatment. Monocytes and neutrophils are important components of the innate immune system and are involved in signaling the adaptive immune system to respond to antigens. A decrease in the activation level of T-cells may indicate reduced inflammatory response, or adaptive immune response towards self-antigens, and

may therefore be important to clinical remission of autoimmune diseases. A decrease in platelet count in response to treatment is also consistent with prior findings [22]. In the future, with better resolution of cell types (e.g. subtypes of T-cells, including Th1, Th17) our approach could again be used to identify which specific cell types are most involved in the treatment response.

The molecular signature we found in response to treatment suggests ongoing pro-inflammatory activity. While many pro-inflammatory markers were down-regulated after treatment, other pro-inflammatory markers such as IL8 were up-regulated. This is not surprising because Jarvis et al. showed persistent *in vitro* pro-inflammatory activity even in patients who were in remission [8]. They postulated that remission might be a state of homeostasis when the effects of the anti-inflammatory network predominated over the effect of the pro-inflammatory network. As evident in our study, the absolute values of fold changes (log₂ differences) of most down-regulated genes were much higher than those of the most up-regulated genes. This is consistent with the notion that the expression of genes that are up-regulated in active JIA is decreased by drug treatment.

We identified a number of differentially expressed genes in the blood samples between pre- and post-treatment individuals. These differentially expressed genes include HLA-DRB and several interleukin and interleukin receptor genes that are known biomarkers for autoimmune diseases. HLA-DRB gene products are involved in antigen presentation and are up-regulated with activation of the adaptive immune response. The reduction in expression of MHC II is also in keeping with down-regulation of the T-cell levels that we observed. The identified interleukins are soluble mediators of inflammation associated with leukocyte recruitment and the innate immune response [23–26]. IL6 is a well-known soluble mediator of inflammation involved in the pathogenesis of arthritis and is currently a target for treatment in both children and adults with arthritis. IL8 is a chemotactic factor that selectively recruits lymphocytes and neutrophils and is an expression signature in JIA [27, 28]. The presence of these well-known biomarkers improves our confidence that the genes identified by our model are involved in JIA disease processes. Interestingly, the most differentially expressed genes identified by our method and by the t-test did not overlap. This shows that our method can be used to complement traditional methods when identifying differential expression signatures.

We also identified two families of genes not previously described as associated with treatment response in JIA: α -defensins and type 1 interferons. α -defensins are homologous peptides expressed by cells participating in the innate immune response including neutrophils, macrophages and intestinal Paneth cells [29]. In addition to their role in innate immunity, recent studies showed that α -defensins may also play a role in the pathogenesis of autoimmune diseases [30]. DEFA1-3 (α -defensins 1–3) increase secretion of pro-inflammatory molecules and enhance the presentation of costimulatory molecules on T-cells [31, 32]. Previous studies indicated that defensins were dysregulated in rheumatoid arthritis compared to control samples [33]; our analysis showed that a decrease in the expression of defensin genes in peripheral blood may be linked to the impact of treatment in JIA. Out of the 6 α -defensins found in humans, the ones we identified (DEFA1-4) are the only ones that are expressed in human neutrophils. Type 1 interferons gene products have been associated with autoimmune diseases such as systemic lupus erythematosus [34]. Our results showed that type 1 interferon gene products may be impacted by treatment in JIA. Recent studies showed that IFN- β was detrimental to Th17 mediated autoimmunity [35], and a review by Espinosa et al. indicated that the inflamed joints in JIA patients expressed high levels of IL17-producing T-cells [36]. Together, these may support the association between levels of type 1 interferon-inducible gene products and arthritis disease activities observed in some patients in our study. Other genes identified by our model, listed in Table 3 and Page 1 in S2 Table, may also be targets for future research.

There are some limitations in this study. Firstly, although the % decrease in active joint count is a readily quantifiable measure of a good treatment response in an individual patient, this measure of effect size does not account for expected variation in the counts (e.g. statistical significance). For example, decreases in active joint counts from 30 to 15 and from 2 to 1 both represent a 50% decrease, even though we intuitively have higher confidence in the decrease from 30 to 15 joints. Secondly, although we have explained a common treatment response profile for a majority of the patients, a few who we predicted to have poor treatment response had good clinical recovery (Fig 4). This pilot study motivates future studies to incorporate multiple treatment-response profiles into the model when larger patient cohort is available. Finally, this study motivates the use of experimental approaches to study and validate the functional impact of the differentially expressed genes we reported in arthritis treatment response.

Conclusion

We applied a novel statistical deconvolution method (ISOpure-S1) to capture a shared molecular signature correlated with a measure of patient outcome in 33 JIA patients having varied characteristics, clinical symptoms and treatments. The results indicated that a decrease in T-cells, monocytes and neutrophils might correlate with a clinical improvement. Furthermore, we identified a list of novel genes that may be impacted by treatments in JIA, including α -defensins. ISOpure-S1 can readily be applied to heterogeneous gene expression profiles in case control, and pre- and post-treatment studies to investigate the pathogenesis and/or disease progression of other complex diseases. The method is especially valuable to study rare diseases that may share common mechanisms by aggregating a small number of patients despite their heterogeneous characteristics.

Supporting Information

S1 Fig. Correlation between expression-based % treatment-response estimate inferred by ISOpure-S1 and % reduction in number of active joints in non-systemic JIA patients. The analysis in Fig 4 is repeated here with the five systemic JIA patients removed, leaving a cohort of patients with more homogeneous clinical presentations.

(PDF)

S2 Fig. The batch effect between patient profiles and reference blood cell type profiles is minimal. We computed the raw differences between each pair of patient profiles, and then calculated the correlation between the raw differences of patient profiles and the reference blood cell type profiles. The Spearman correlation is indicated by color.

(PDF)

S1 File. MATLAB script to run ISOpure-S1. MATLAB script including a description of input and output data.

(PDF)

S2 File. DAVID functional enrichment analysis. Functional annotation on the top 100 down- and up-regulated genes after treatment.

(PDF)

S1 Table. Spearman correlations between clinical indicators of disease activity.

(PDF)

S2 Table. Differentially expressed genes identified by ISOpure-S1 and the standard t-test. ISOpure-S1 results (page 1) and the standard t-test results (page 2).

(XLSX)

Acknowledgments

The following members of the BBOP consortia contributed to detailed patient data acquisition and biologic specimen collection including: Paul Dancey of Janeway Children's Hospital and Rehabilitation Centre, St. John's; Adam Huber, Bianca Lang, Suzanne Ramsey, and Elizabeth Stringer of IWK Health Centre, Halifax; Anne-Laure Chetaille of le Centre Hospitalier Universitaire de Quebec, Quebec; Gilles Boire of l'Université de Sherbrooke, Quebec; Sarah Campillo, Gaëlle Chédeville, and Rosie Scuccimarrì of Montreal Children's Hospital and McGill University Health Centre, Montreal; Ciarán Duffy, Karen Watanabe Duffy, Michele Gibbon, Roman Jurencak and Johannes Roth of Children's Hospital of Eastern Ontario and the University of Ottawa, Ottawa; Susanne Benseler, Bonnie Cameron, Brian Feldman, Ronald Laxer, Rayfel Schneider, Lynn Spiegel and Shirley Tse of the Hospital for Sick Children and the University of Toronto, Toronto; Kiem Oen of the University of Manitoba, Winnipeg; Elham Rezaei and Loren Matheson of the University of Saskatchewan, Saskatoon; Janet Ellsworth of the University of Alberta, Edmonton; and David A. Cabral, Jaime Guzman, Kristin Houghton, Ross Petty, Lori B. Tucker, and Stuart Turvey of British Columbia Children's Hospital and the University of British Columbia, Vancouver.

The authors would like to thank Dr. Steven H. Kleinstein for his helpful comments on the manuscript.

Ethics review boards and approval numbers:

Clinical Research Ethics Board, University of British Columbia: #H07-01204

Health Research Ethics Board, University of Alberta: #6984

Biomedical Research Ethics Board, University of Saskatchewan: #07-86

Biomedical Research Ethics Board, University of Manitoba: #H2007:111

Research Ethics Board, Hospital for Sick Children: #1000011118

Research Ethics Board, Children's Hospital of Eastern Ontario: #09-16E

Biomedical Research Ethics Board, McGill University: #PED-07-020

Research Ethics Committee, Université Laval: #123.05.09

Institutional Ethics Committee of Research Involving Humans, University of Sherbrook: #07-119

IWK Health Centre Research Ethics Board: #1001241

Human Investigation Committee, Memorial University: #06.047

Author Contributions

Conceived and designed the experiments: QM. Performed the experiments: AC GQ. Analyzed the data: AC GQ QM RY AR. Contributed reagents/materials/analysis tools: AR RY BBOP. Wrote the paper: AC GQ QM RY AR BBOP.

References

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur A-M, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol* 2004, 31:390–2. PMID: [14760812](#)
2. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schöntube M, Zink A: Long-term outcome in patients with juvenile idiopathic arthritis. *Arthritis Rheum* 2002, 46:2392–401. PMID: [12355487](#)
3. Oen K: Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. *Best Pract Res Clin Rheumatol* 2002, 16:347–360. PMID: [12387804](#)
4. Packham JC, Hall M a: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. *Rheumatology (Oxford)* 2002, 41:1428–35.

5. Flatø B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, Sørskaar D, Moum T, Ploski R, Førre Ø: Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. *J Rheumatol* 2003, 30:386–93. PMID: [12563700](#)
6. Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. *Rheumatology (Oxford)* 2000, 39:198–204. PMID: [10725073](#)
7. Prakken B, Albani S, Martini: Juvenile idiopathic arthritis. *Lancet* 2011, 377:2138–49. doi: [10.1016/S0140-6736\(11\)60244-4](#) PMID: [21684384](#)
8. Jarvis JN, Jiang K, Frank MB, Knowlton N, Aggarwal A, Wallace C a, McKee R, Chaser B, Tung C, Smith LB, McGhee JL, Chen Y, Osban J, O'Neil KM, Centola M: Gene expression profiling in neutrophils from children with polyarticular juvenile idiopathic arthritis. *Arthritis Rheum* 2009, 60:1488–95. doi: [10.1002/art.24450](#) PMID: [19404961](#)
9. Moncrieffe H, Hinks A, Ursu S, Kassoumeri L, Etheridge A, Hubank M, Martin P, Weiler T, Glass DN, Thompson SD, Thomson W, Wedderburn LR: Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. *Pharmacogenet Genomics* 2010, 20:665–76. doi: [10.1097/FPC.0b013e32833f2cd0](#) PMID: [20827233](#)
10. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarrì R, Berard R, Tse SML, Morishita K, Stringer E, Johnson N, Levy DM, Duffy KW, Cabral D a, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille A-L, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmelting H, Lang B, Ellsworth J, et al.: The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. *Ann Rheum Dis* 2014:1–7.
11. Quon G, Morris Q: ISOLATE: a computational strategy for identifying the primary origin of cancers using high-throughput sequencing. *Bioinformatics* 2009, 25:2882–9. doi: [10.1093/bioinformatics/btp378](#) PMID: [19542156](#)
12. Quon G, Haider S, Deshwar AG, Cui A, Boutros PC, Morris Q: Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. *Genome Med* 2013, 5:29. doi: [10.1186/gm433](#) PMID: [23537167](#)
13. Qiao W, Quon G, Csaszar E, Yu M, Morris Q, Zandstra PW: PERT: a method for expression deconvolution of human blood samples from varied microenvironmental and developmental conditions. *PLoS Comput Biol* 2012, 8:e1002838. doi: [10.1371/journal.pcbi.1002838](#) PMID: [23284283](#)
14. Bolen CR, Uduman M, Kleinstein SH: Cell subset prediction for blood genomic studies. *BMC Bioinformatics* 2011, 12:258. doi: [10.1186/1471-2105-12-258](#) PMID: [21702940](#)
15. Shen-Orr SS, Gaujoux R: Computational deconvolution: extracting cell type-specific information from heterogeneous samples. *Curr Opin Immunol* 2013, 25:571–8. doi: [10.1016/j.coi.2013.09.015](#) PMID: [24148234](#)
16. Matheson L a Duong TT, Rosenberg AM, Yeung RSM: Assessment of sample collection and storage methods for multicenter immunologic research in children. *J Immunol Methods* 2008, 339:82–9. doi: [10.1016/j.jim.2008.08.003](#) PMID: [18771669](#)
17. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, Habib N, Yosef N, Chang CY, Shay T, Frampton GM, Drake ACB, Leskov I, Nilsson B, Preffer F, Dombkowski D, Evans JW, Liefeld T, Smutko JS, Chen J, Friedman N, u R a, Golub TR, Regev A, Ebert BL: Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell* 2011, 144:296–309. doi: [10.1016/j.cell.2011.01.004](#) PMID: [21241896](#)
18. Giannini EH, Ruperto N, Ravelli a, Lovell DJ, Felson DT, Martini a: Preliminary definition of improvement in juvenile arthritis. *Arthritis Rheum* 1997, 40:1202–9. PMID: [9214419](#)
19. Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009, 4:44–57. doi: [10.1038/nprot.2008.211](#) PMID: [19131956](#)
20. Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009, 37:1–13. doi: [10.1093/nar/gkn923](#) PMID: [19033363](#)
21. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. *Arthritis Res Ther* 2008, 10:R101. doi: [10.1186/ar2493](#) PMID: [18759964](#)
22. Endresen GK, Høyeraal HM, Kåss: Platelet count and disease activity in juvenile rheumatoid arthritis. *Scand J Rheumatol* 1977, 6:237–40. PMID: [607392](#)
23. Arthritis P-I-R, Seitz M, Dewald B, Gerber N, Baggiolini M: Enhanced Production of Neutrophil-activating. 1991, 87(February):463–469.

24. Brennan FM, Zachariae CO, Chantry D, Larsen CG, Turner M, Maini RN, Matsushima K, Feldmann M: Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. *Eur J Immunol* 1990, 20:2141–4. PMID: [2209707](#)
25. Beaulieu AD, McColl SR: Differential expression of two major cytokines produced by neutrophils, interleukin-8 and the interleukin-1 receptor antagonist, in neutrophils isolated from the synovial fluid and peripheral blood of patients with rheumatoid arthritis. *Arthritis Rheum* 1994, 37:855–9. PMID: [8003057](#)
26. Skov L, Beurskens FJ, Zachariae COC, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot EPJ, Hudson D, Baadsgaard O, Parren PWI, van de Winkel JGJ: IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. *J Immunol* 2008, 181:669–79. PMID: [18566434](#)
27. Matsushima K, Oppenheim JJ: Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. *Cytokine* 1989, 1:2–13. PMID: [2491503](#)
28. de Jager W, Hoppenreijns EP a H, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ: Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. *Ann Rheum Dis* 2007, 66:589–98. PMID: [17170049](#)
29. Lehrer RI, Lichtenstein A K, Ganz T: Defensins: antimicrobial and cytotoxic peptides of mammalian cells. *Annu Rev Immunol* 1993, 11:105–28. PMID: [8476558](#)
30. Vordenbäumen S, Schneider M: Defensins: Potential Effectors in Autoimmune Rheumatic Disorders. *Polymers (Basel)* 2011, 3:1268–1281.
31. Lillard JW, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR: Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. *Proc Natl Acad Sci U S A* 1999, 96:651–6. PMID: [9892688](#)
32. Vaschetto R, Grinstein J, Del Sorbo L, Khine AA, Voglis S, Tullis E, Slutsky AS, Zhang H: Role of human neutrophil peptides in the initial interaction between lung epithelial cells and CD4+ lymphocytes. *J Leukoc Biol* 2007, 81:1022–31. PMID: [17215524](#)
33. Bovin LF, Rieneck K, Workman C, Nielsen H, Sørensen SF, Skjødt H, Florescu A, Brunak S, Bendtzen K: Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. *Immunol Lett* 2004, 93:217–26. PMID: [15158620](#)
34. Bennett L, Palucka a K, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. *J Exp Med* 2003, 197:711–23. PMID: [12642603](#)
35. Axtell RC, Raman C, Steinman L: Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. *Clin Rev Allergy Immunol* 2013, 44:114–20. doi: [10.1007/s12016-011-8296-5](#) PMID: [22231516](#)
36. Espinosa M, Gottlieb BS: Juvenile idiopathic arthritis. *Pediatr Rev* 2012, 33:303–13. doi: [10.1542/pir.33-7-303](#) PMID: [22753788](#)